| Newer antidepressants and the cytochrome P450 system. CB Nemeroff, CL DeVane, BG Pollock The American journal of psychiatry 153 (3), 311-320, 1996 | 694 | 1996 |
| Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme JS Markowitz, JL Donovan, CL DeVane, RM Taylor, Y Ruan, JS Wang, ... Jama 290 (11), 1500-1504, 2003 | 516 | 2003 |
| Clinical pharmacokinetics of quetiapine: an atypical antipsychotic CL DeVane, CB Nemeroff Clinical pharmacokinetics 40, 509-522, 2001 | 514 | 2001 |
| In vitro P-glycoprotein affinity for atypical and conventional antipsychotics DW Boulton, CL DeVane, HL Liston, JS Markowitz Life sciences 71 (2), 163-169, 2002 | 315 | 2002 |
| Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes DJ Newport, MR Calamaras, CL DeVane, J Donovan, AJ Beach, S Winn, ... American Journal of Psychiatry 164 (8), 1214-1220, 2007 | 295 | 2007 |
| Clinical pharmacokinetics of sertraline CL De Vane, HL Liston, JS Markowitz Clinical pharmacokinetics 41, 1247-1266, 2002 | 279 | 2002 |
| Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis HJ Zhu, KS Patrick, HJ Yuan, JS Wang, JL Donovan, CL DeVane, ... The American Journal of Human Genetics 82 (6), 1241-1248, 2008 | 256 | 2008 |
| Drug glucuronidation in clinical psychopharmacology HL Liston, JS Markowitz, CL DeVane Journal of clinical psychopharmacology 21 (5), 500-515, 2001 | 229 | 2001 |
| Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers JS Markowitz, CL DeVane, DW Boulton, SW Carson, Z Nahas, SC Risch Life sciences 66 (9), PL133-PL139, 2000 | 219 | 2000 |
| Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors CL DeVane Cellular and molecular neurobiology 19, 443-466, 1999 | 210 | 1999 |
| Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana HJ Zhu, JS Wang, JS Markowitz, JL Donovan, BB Gibson, HA Gefroh, ... Journal of Pharmacology and Experimental Therapeutics 317 (2), 850-857, 2006 | 207 | 2006 |
| Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression. CL Devane, E Chiao, M Franklin, EJ Kruep The American journal of managed care 11 (12 Suppl), S344-53, 2005 | 203 | 2005 |
| Substance P: a new era, a new role CL DeVane Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21 (9 …, 2001 | 194 | 2001 |
| Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro JS Wang, CL DeVane Drug Metabolism and Disposition 31 (6), 742-747, 2003 | 187 | 2003 |
| Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency FR SALLEE, CL DeVANE, RE FERRELL Journal of child and adolescent psychopharmacology 10 (1), 27-34, 2000 | 180 | 2000 |
| The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein JS Wang, Y Ruan, RM Taylor, JL Donovan, JS Markowitz, CL DeVane International Journal of Neuropsychopharmacology 7 (4), 415-419, 2004 | 174 | 2004 |
| Treatment of aggressive children with clonidine: results of an open pilot study JP Kemph, CL DeVane, GM Levin, R Jarecke, RL Miller Journal of the American Academy of Child & Adolescent Psychiatry 32 (3), 577-581, 1993 | 173 | 1993 |
| Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses HS Gill, CL DeVane, SC Risch Journal of clinical psychopharmacology 17 (5), 377-389, 1997 | 172 | 1997 |
| Pharmacokinetics, drug interactions, and tolerability of valproate. CL DeVane Psychopharmacology bulletin 37, 25-42, 2003 | 168 | 2003 |
| Pro-inflammatory biomakers in depression: treatment with venlafaxine JE Piletz, A Halaris, O Iqbal, D Hoppensteadt, J Fareed, H Zhu, J Sinacore, ... The World Journal of Biological Psychiatry 10 (4), 313-323, 2009 | 166 | 2009 |
Mark S. GeorgeMedical University of South CarolinaVerified email at musc.edu
